Matrix metalloproteinase-9 is associated with CX3CL1 on tau and amyloid biomarker pathways in APOE4 carriers.
Aimee K Johnson, Carol A Van Hulle, Hannah Zylstra et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the relationship between matrix metalloproteinase-9 (MMP-9) and CX3CL1 in cerebrospinal fluid biomarkers for amyloid and tau in cognitively unimpaired APOE ε4 carriers (APOE4+) versus non-carriers (APOE4-). The study found that Aβ42 and Aβ42/Aβ40 levels were lower in APOE4+ carriers, while p-tau217 was higher, indicating distinct biomarker profiles linked to inflammation in this population.
Key findings
- Aβ42 and Aβ42/Aβ40 levels were lower in APOE4+ carriers compared to non-carriers.
- p-tau217 levels were higher among APOE4+ participants than in APOE4- participants.
- MMP-9 mediated the effect of CX3CL1 on amyloid and tau biomarkers in APOE4+ carriers.
- CX3CL1 correlated with a pro-inflammatory z score in APOE4+ and an anti-inflammatory z score in APOE4-.
Why it matters
Understanding the inflammatory pathways involving MMP-9 and CX3CL1 in APOE4 carriers may provide insights into early Alzheimer's disease mechanisms, potentially guiding future therapeutic strategies and risk assessments in this high-risk population.